Canada markets open in 9 minutes

Aquestive Therapeutics, Inc. (AQST)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.1000+0.0400 (+0.99%)
At close: 04:00PM EDT
4.2200 +0.12 (+2.93%)
Pre-Market: 09:19AM EDT

Aquestive Therapeutics, Inc.

30 Technology Drive
Warren, NJ 07059
United States
(908) 941-1900
https://www.aquestive.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees135

Key Executives

NameTitlePayExercisedYear Born
Mr. Daniel BarberCEO, President & Director925.35kN/A1976
Mr. Alexander Mark SchobelChief Innovation & Technology Officer672.69kN/A1959
Ms. Lori J. Braender BSBA, Esq., J.D.Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary678.76kN/A1956
Mr. A. Ernest Toth Jr.Chief Financial Officer679.9kN/A1959
Ms. Cassie JungSenior Vice President of OperationsN/AN/A1979
Mr. Peter E. BoydSenior Vice President of IT, HR & CommunicationsN/AN/A1966
Dr. Gary H. Slatko M.D., MBAChief Medical OfficerN/AN/A1958
Dr. Stephen WargackiSenior VP of Research & DevelopmentN/AN/A1978
Dr. Carl N. Kraus M.D.Chief Medical OfficerN/AN/A1970
Mr. Robert Charles ArnoldVP of Finance, Controller & Assistant SecretaryN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Corporate Governance

Aquestive Therapeutics, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 7. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.